http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8758815-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d120d8712ee54410ea1a910ed678e1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dee3727dba91e4e7aa3b26ce9efbcc21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a53d6e10ccd3cecfe52f28fb88d9be96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c4d58604d6f35836bb059ea60c308d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7182760be5429bfbf7ad7a7b230c459f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2011-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1367173c6f15408c48058b62b5589c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2a4692441c5e5277654683bbeed8ff6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9185c56a79127df56b09751cef48ef9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a34cb0b4f5cd99e386588854a89d88 |
| publicationDate | 2014-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8758815-B2 |
| titleOfInvention | Pharmaceutical compositions comprising a combination of metformin and sitagliptin |
| abstract | The present invention relates to a pharmaceutical composition, preferably a pharmaceutical dosage form, comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin. n The present invention also relates to a process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:n a) providing one composition containing metformin or a pharmaceutically acceptable salt thereof and optionally also sitagliptin, b) providing a further composition containing sitagliptin or a pharmaceutically acceptable salt thereof and optionally also metformin, and c) combining the compositions to form compartments. nn The present invention also refers to a process for preparing dosage forms comprising at least one compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprises providing a composition containing metformin or a pharmaceutically acceptable salt thereof, and sitagliptin or a pharmaceutically acceptable salt thereof, and a matrix agent. n Moreover, the present invention related to a dosage form obtained by said process, and to the use of said dosage form for the treatment of diabetes. |
| priorityDate | 2010-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 161.